ADVERTISEMENT
4 /5 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Investment

Lilly partners with Aduro Biotech to develop STING inhibitors for autoimmune diseases

by Ryan Cross
January 7, 2019 | APPEARED IN VOLUME 97, ISSUE 1

 

09701-buscon15-sting.jpg
Credit: Aduro Biotech/Christian Lee/Genomics Institute of the Novartis Research Foundation
The crystal structure of human STING, with the agonist ADU-S100 from Aduro.

Eli Lilly and Company is partnering with Berkeley, California-based Aduro Biotech to discover small-molecule inhibitors of a protein called STING, which stands for stimulator of interferon genes. The STING pathway is involved in innate immunity. Several drug companies are developing activators of STING in hopes that boosting innate immunity will help the body fight cancer. Lilly wants to inhibit STING to treat autoimmune diseases in which the innate immune system is overactive. Aduro will earn $12 million up front and up to $620 million per developed product.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment